Descriptive study of events allegedly attributable to mpox vaccination in Brazil in 2023

This study describes the surveillance and safety actions of the mpox (Jynneos) vaccine in Brazil, from 2022 to 2023. A descriptive study of mpox cases and events supposedly attributable to vaccination and/or immunization for Jynneos vaccine, recorded in the information systems, was conducted. Absolu...

Descripción completa

Detalles Bibliográficos
Autores: Mendes Abreu Silva, Roberta, Dinamerica Kobayashi, Carla, Ferreira Martins, Adriano, Catarina de Melo Araújo, Ana, Henrique Santos Andrade, Paulo, Elizabeth Brasil da Nóbrega, Martha, Mendes Cabral, Cibelle, Brauner de Moraes, Monica, Daniel Cardoso, Felipe, Neiva da Fonseca Victer, Thayssa, Krummenauer, Amanda, Otávio Pereira Sayago Soares, Rodrigo, Gatti Fernandes, Eder, Percio, Jadher
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:Brasil
Institución:Fundação Oswaldo Cruz (FIOCRUZ)
Repositorio:Cadernos de Saúde Pública
Idioma:portugués
OAI Identifier:oai:ojs.teste-cadernos.ensp.fiocruz.br:article/8724
Acceso en línea:https://cadernos.ensp.fiocruz.br/ojs/index.php/csp/article/view/8724
Access Level:acceso abierto
Palabra clave:Mpox; Vacinas Atenuadas; Vacinação; Farmacovigilância; Evento Adverso
Mpox; Vacunas Atenuadas; Vacunación; Farmacovigilancia; Evento Adverso
Mpox; Attenuated Vaccines; Vaccination; Pharmacovigilance; Adverse Event
Descripción
Sumario:This study describes the surveillance and safety actions of the mpox (Jynneos) vaccine in Brazil, from 2022 to 2023. A descriptive study of mpox cases and events supposedly attributable to vaccination and/or immunization for Jynneos vaccine, recorded in the information systems, was conducted. Absolute and relative frequencies and reporting coefficients of events supposedly attributable to vaccination and/or immunization per 1,000 administered doses were calculated. A total of 9,596 cases of mpox were registered and 49,000 doses of vaccine were distributed, of which 14,395 (31%) were administered and 65 events supposedly attributable to vaccination and/or immunization (4.5 per 1,000 administered doses) were notified. All events supposedly attributable to vaccination and/or immunization were non-serious, and 22 (33.8%) cases had product-related reactions. Results are within the expected frequency; however, the number of administered doses may not have been sufficient to detect rare or unusual events. Continued surveillance is necessary to ensure vaccination effectiveness and safety, especially among groups at higher risk for the disease.

Similares en LA Referencia